Article in Biomolecular NMR assignments, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
Alexander M BarclayCenter for Biophysics and Quantitative Biology, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.
Dhruva D DhavaleDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Collin G BorcikDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, 53706, USA.
Moses H MilchbergDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, 53706, USA.
Paul T KotzbauerDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, 63110, USA. kotzbauerp@wustl.edu.
Chad M RienstraDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI, 53706, USA. crienstra@wisc.edu.
University of Illinois Urbana-Champaign · USUniversity of Wisconsin–Madison · USWashington University in St. Louis · US
Funding
INVESTIGATIONS OF DEMENTIA IN PARKINSON DISEASER01NS075321 · NINDS · WASHINGTON UNIVERSITY · PI CAMPBELL, MEGHAN C, PERLMUTTER, JOEL SYNES · 2011 to 2021
$8.2M
Technologies for Solid-State NMR Data CollectionP41GM136463 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI WESTLER, WILLIAM MILO · 2021 to 2025
$6.4M
Protein Aggregation and Neurotransmitter Deficits in Parkinson DiseaseR01NS097799 · NINDS · WASHINGTON UNIVERSITY · PI PAUL T KOTZBAUER · 2016 to 2026
$5.8M
Structural Biology of Alpha-Synuclein in Lewy Body DementiaRF1NS110436 · NINDS · WASHINGTON UNIVERSITY · PI KOTZBAUER, PAUL T, RIENSTRA, CHAD M · 2023 to 2023
$4.2M
STRUCTURAL BIOLOGY OF ALPHA-SYNUCLEIN IN LEWY BODY DEMENTIAU01NS110436 · NINDS · WASHINGTON UNIVERSITY · PI KOTZBAUER, PAUL T · 2018 to 2022
$4.1M
Investigations of Dementia in Parkinson DiseaseRF1NS075321 · NINDS · WASHINGTON UNIVERSITY · PI CAMPBELL, MEGHAN C, PERLMUTTER, JOEL SYNES · 2023 to 2023
$2.3M
Structural Biology of Alpha-Synuclein in Lewy Body DementiaR01NS110436 · NINDS · WASHINGTON UNIVERSITY · PI PAUL T KOTZBAUER, ELIZABETH R WRIGHT · 2026 to 2026
$1.4M
Structural Biology and Biophysics of Alpha-Synuclein Fibrils by Solid-State NMRF32GM149118 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BORCIK, COLLIN GRIFFIN · 2023 to 2024
Fibrils of the protein α-synuclein (Asyn) are implicated in the pathogenesis of Parkinson Disease, Lewy Body Dementia, and Multiple System Atrophy. Numerous forms of Asyn fibrils have been studied by solid-state NMR and resonance assignments have been reported. Here, we report a new set of
Indexed as
Lewy Body DiseaseMultiple System AtrophyParkinson Diseasealpha-SynucleinHumansNuclear Magnetic Resonance, Biomolecularalpha-SynucleinFibrilsLewy Body DementiaParkinson DiseasePolymorphismαSynuclein
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.